Table 2 Impact of CLDN18-ARHGAP26/6 fusion on chemotherapy treatment outcomes

From: Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer

Patientsa (No. of patients with/without chemotherapy)

Univariate

Multivariateb

HR (95% CI)

P value

HR (95% CI)

P value

All (N = 422/382)

1.26 (1.03–1.53)

0.02

1.37 (1.13–1.67)

0.002

Fusion (N = 41/31)

0.98 (0.54–1.79)

0.95

1.03 (0.55–1.94)

0.92

Wildtype (N = 381/351)

1.30 (1.05–1.60)

0.01

1.41 (1.15–1.75)

0.001

  1. P values and HRs were estimated by Cox regression model
  2. HR hazard ratio, 95% CI 95% confidence interval of the risk ratio
  3. a804 out of 829 patients (combining 32 patients for whole genome sequencing and 797 patients for validations) have full follow-up information, with platinum/fluoropyrimidines treatment or no chemotherapy treatment at all
  4. bTNM stage and SRCC were adjusted in multivariate analyses
Back to article page